Premium
Clinical, pharmacologic, and immunologic effects of 2'‐deoxycoformycin
Author(s) -
Cummings F J,
Crabtree G W,
Wiemann M C,
Spremulli E N,
Parks R E,
Calabresi Paul
Publication year - 1988
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1988.187
Subject(s) - deoxycoformycin , adenosine deaminase , pharmacology , medicine , adenosine deaminase inhibitor , adenosine , clinical pharmacology , lymphocyte , pentostatin , toxicity , immunology
Clinical, pharmacologic, and immunologic effects of 2'‐deoxycoformycin (dCF) were evaluated in 15 patients with advanced malignancies. Toxicity was less severe with a low dose (4 mg/m 2 ) of dCF, but this dose still resulted in suppression of cellular adenosine deaminase activity, skin test reactivity, and lymphocyte responses to mitogens. Improvement in cutaneous T cell lymphoma plaques was seen after dCF. Further investigations of antitumor efficacy with the use of this low dosage schedule should continue in patients with hematologie neoplasms, and additional preliminary studies of the combination of an adenosine deaminase inhibitor with an adenosine analog should also be considered. Clinical Pharmacology and Therapeutics (1988) 44, 501–509; doi: 10.1038/clpt.1988.187